CompletedNot Applicable

Coronary Artery Bypass Grafting Strategies for the Anterolateral Territory: a Prospective Randomized Clinical Trial

Canada208 participantsStarted 2012-07

Plain-language summary

The purpose of the AMI-PONT trial is to assess whether the results in term of graft patency with a novel coronary artery bypass (CABG) strategy, including a saphenous vein bridge to distribute the arterial flow of the left anterior mammary artery (LIMA) to all the anterolateral territory, are not inferior than a conventional CABG strategy combining separated LIMA graft to left anterior descending coronary and vein graft for other target vessels of the anterolateral territory.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. require isolated CABG with median sternotomy on at least one left anterior descending (LAD) site and another anterolateral target;
✓. provide written informed consent;
✓. are more than 21 years of age.

Exclusion criteria

✕. concomitant cardiac procedure associated with CABG including valve surgery and ascending aorta surgery;
✕. contra-indications to cardiopulmonary bypass (calcified aorta);
✕. unusable left internal mammary artery (LIMA) such as uncorrected subclavian artery stenosis, anterior chest trauma, radiation or injury during harvesting precluding the use of the LIMA;
✕. concomitant life-threatening disease likely to limit life expectancy to less than 2 years;
✕. emergency CABG surgery (immediate revascularization for hemodynamic instability precluding patient consent);
✕. prior CABG;
✕. severe congestive heart failure with left ventricular ejection fraction less than 30%.
✕. moderate to severe renal impairment (estimated glomerular filtration rate, eGFR \<50 mL/min/1.73 m2);

What they're measuring

Anterolateral territory graft patency index

Timeframe: 1 year

Trial details

NCT IDNCT01585285

SponsorCentre hospitalier de l'Université de Montréal (CHUM)

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-04

View on ClinicalTrials.gov More Coronary Artery Disease trials